PMPRB release analyzes key cost pressures driving changes in public plan prescription drug expenditures
PMPRB report shows that the 10 highest-cost drugs reimbursed by public drug plans in Canada were all rare disease treatments with annual treatment costs of over $250,000.
Read the original at the source: https://www.canada.ca/en/patented-medicine-prices-review/news/2023/12/pmprb-release-analyzes-key-cost-pressures-driving-changes-in-public-plan-prescription-drug-expenditures.html
Officially imported this from Patented Medicine Prices Review Board’s own source. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
Provenance
- Organization
- Patented Medicine Prices Review Board — imported from official source
- Official source
- https://api.io.canada.ca/io-server/gc/news/en/v2?dept=patentedmedicinepricesreviewboard&sort=publishedDate&orderBy=desc&publishedDate%3E=2021-07-23&pick=50&format=atom&atomtitle=Patented%20Medicine%20Prices%20Review%20Board ATOM
- Imported
- October 03, 2026 20:43
- Versions
- 1 recorded
- Identity
https://www.canada.ca/en/patented-medicine-prices-review/news/2023/12/pmprb-release-ana...